Brainstorm Cell Therapeutics (NASDAQ:BCLI) Shares Cross Above Two Hundred Day Moving Average of $0.32

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI)’s share price passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $0.32 and traded as high as $0.58. Brainstorm Cell Therapeutics shares last traded at $0.54, with a volume of 365,604 shares changing hands.

Wall Street Analysts Forecast Growth

Separately, StockNews.com started coverage on Brainstorm Cell Therapeutics in a report on Wednesday, March 27th. They set a “sell” rating for the company.

Brainstorm Cell Therapeutics Trading Up 3.8 %

The stock has a market capitalization of $37.25 million, a P/E ratio of -1.33 and a beta of 0.28. The company has a fifty day simple moving average of $0.47 and a two-hundred day simple moving average of $0.33.

Institutional Trading of Brainstorm Cell Therapeutics

A hedge fund recently bought a new stake in Brainstorm Cell Therapeutics stock. Kingswood Wealth Advisors LLC purchased a new stake in Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 81,050 shares of the biotechnology company’s stock, valued at approximately $46,000. Kingswood Wealth Advisors LLC owned about 0.12% of Brainstorm Cell Therapeutics at the end of the most recent reporting period. 14.33% of the stock is currently owned by institutional investors.

About Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.